These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, Kotlyar E, McSwain CS, Laliberte K, Arneson C, Rubin LJ, FREEDOM-C2 Study Team. Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822 [Abstract] [Full Text] [Related]
7. Implantable LENUS pro pump for treprostinil infusion in three pediatric patients. Álvarez-Fuente M, Garrido-Lestache E, Rivero N, Centella T, Lamas MJ, Pérez-Caballero C, Vázquez JL, Del Cerro MJ. Pediatr Pulmonol; 2020 May; 55(5):1254-1258. PubMed ID: 32149476 [Abstract] [Full Text] [Related]
14. Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension. Richter MJ, Ewert R, Warnke C, Gall H, Classen S, Grimminger F, Mayer E, Seeger W, Ghofrani HA. Clin Res Cardiol; 2017 Mar; 106(3):174-182. PubMed ID: 27670656 [Abstract] [Full Text] [Related]
15. The role of treprostinil in the management of pulmonary hypertension. Skoro-Sajer N, Lang I. Am J Cardiovasc Drugs; 2008 Mar; 8(4):213-7. PubMed ID: 18690755 [Abstract] [Full Text] [Related]
19. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, Zamanian RT. Am J Cardiol; 2012 Nov 15; 110(10):1546-50. PubMed ID: 22853986 [Abstract] [Full Text] [Related]